지상발표 : 특발성 세균성 복막염의 감별진단 지표

장영호(Yung Ho Chang),유영근(Young Geun Ryoo),최관수(Gwan Su Choi),박광숙(Kwang Sook Park),김지운(Ji Woon Kim),정남기(Nam Ki Jong) 대한소화기학회 1987 대한소화기학회 추계학술대회 Vol.1987 No.-

구연발표 : B 형 간염 백신의 효과 - 산모의 HBeAg 양성 유무에 따라 -

장영호(Yung Ho Chang),유영근(Young Geun Ryoo),최관수(Gwan Su Choi),박광숙(Kwang Sook Park),김지운(Ji Woon Kim),정남기(Nam Ki Jong) 대한소화기학회 1987 대한소화기학회 추계학술대회 Vol.1987 No.-

간장및 담도 : 산모와 신생아에서 C형간염바이러스의 수직감염에 관한 연구

정남기(nam Ki Joung),장영호(Yung Ho Chang),유영근(Young Geun Ryoo),정만(Mann Jung),심승식(Seung Shik Shim),오은아(Eun A Ho) 대한소화기학회 1990 대한소화기학회지 Vol.22 No.2

N/A In order to confirm the perinatal transmission of hepatitis C virus from pregnant women to newborn infants, anti-HCV was tested in 45 pregnant women and their 46 newborn infants who were negative for HBsAg and IgM anti-HA and who showed elevated ALT in more than 2 follow-up tests. The results were as follows; 1) The mean age of 45 pregnant women was 26.8. There was no significant relationship between epidemiologic factors and elevated ALT in pregnant women. 2) Among 45 HBsAg and IgM anti-HA negative pregnant women, 22 were anti-HBs and anti-HBc positive, 14 were anti-HBc positive only, and 9 were anti-HBs and anti-HBc negative. The degree of abnormal ALT in mothers and infants was unrelated to the hepatitis B viral markers in mothers. There was no significant relationship in the degree of ALT elevation between mothers and infants. 3) Anti-HCV was positive in 7 cases (15.6%) of 45 pregnant women. Anti-HCV was positive in 6 cases (15.2%) of 46 newborn infants. In the 7 anti-HCV positive mothers, anti-HCV was positive for one year or a maximum of four years and ALT was elevated intermittently for more than one year, the same as chronic viral hepatitis. But in the 6 cases of anti-HCV positive infants, anti-HCV disappered within 6 or 12 months in most cases and ALT elevation didnt continue for more than 6 months. 4) Anti-HCV was positive in 4 cases (50%) of 8 newborn infants of anti-HCV positive mothers (p< 0.01). Anti-HCV was positive in 2 (67.7%) of 3 cases whose blood was drawn and stored immediately after birth. The positive rate of anti-HCV was about 15% in 45 pregnant women and their infants who were NANB hepatitis suspects by surrogate tests. Anti-HCV was positive in 50% and ALT was abnormal in all eight infants of chronic HCV carrier mothers. We confirmed the passive transfer of anti-HCV from mother to infant. But we need more evidence to confirm the perinatal transmission of HCV.

한국인 산모와 신생아에서 NANB 간염과 B 형 간염에 관한 연구

최관수(Gwan Su Choi),김지운(Ji Woon Kim),장영호(Yung Ho Chang),오은아(Eun A O),양인애(In Ae Yang),유영근(Young Geun Ryoo),이봉섭(Bong Seob Lee),정남기(Nam Ki Jong),오영종(Young Zong Oh),남명숙(Myoung Soog Nam),임순선(Soon Seon Lim),김 대한소화기학회 1988 대한소화기학회지 Vol.20 No.2

N/A To assess the frequency of hepatitis in pregnant women, we examined the findings of the physical examination, medical history, liver function tests and viral markers in 7,580 pregnant women who delivered at St. Columbans Hospital in Mokpo City from April 1st, 1985 to June 30th, 1988. We compared the characteristics of hepatitis B in 28 mothers and 17 newborn infants, and of non-A, non-B hepatitis in 17 mothers and 61 newborn infants, The results were as follows; 1) Among 7,580 pregnant women, there were 629 cases (8.30%) of HBV carriers. Abnormal elevation of transaminase at delivery was noted in cases of hepatitis A (2, 0.03%), hepatitis B (25, 0. 33%), NANB hepatitis (57, 0.75%) toxemia (9, 0.12%) and drug induced hepatitis (1, 0,01%). 2) The earliest elevation of transaminase was noted at 3 months in 9 hepatitis B infants (6, 66.7%) and 61 NANB hepatitis infants (57, 93.4%). The highest elevation of transaminase was noted at 3 months in 61 NANB hepatitis infants (41, 67. 2%) and seemed to be delayed in 9 hepatitis B infants due to the effect of vaccine. 3) Abnormal transaminase was normal within 6 months in 17 cases (60.7%) of 28 mothers with hepatitis B, and 14 cases (82.4%) of 17 mothers with NANB hepatitis. If we test and observe for )onger time the cases of chronic hepatitis with intermittent elevation of transaminase may increase more. Twenty-seven of 28 hepatitis B mothers were positive for HBsAg for more than 1 year. Duration of abnormal transaminase in hepatitis B infants was much different by the vaccination, but total number of cases was very small. Among 61 NANB hepatitis infants, continuous elevation of transaminase was noted in 5(62.5%) of 8 infants who had no imrnunoprophylaxis, 19(55.9%) of 34 infants who received HBIG & Hepavax, 5(26.3%) of 19 infants who received gamma-globulin. There was slight but not significant inhibition of persistence of abnormal transaminase in group of gamma-globulin injection (0.05<p<0.1). The mean level of maximal ALT was higher in hepatitis B (148.32+162.47 IU) than in NANB hepatitis mothers (76.53<53.14 IU). It was similar in infants of both hepatitis B & NANB, and lower in infants who received Hepavax, gamma-globulin but it was not statistically significant. 4) Among the factors which may influence the elevation of ALT in hepatitis infants the level of ALT in hepatitis mothers had no influence. The immunoprophylaxis with HBIG & hepavax for hepatitis B infants, gamma-globulin for NANB hepatitis seemed to inhibit the elevation of ALT in infants, but not signficantly. ALT was normal in 5 infants (23.8%) of 21 HBeAg positive hepatitis B mothers and in 6 infants (85.7%) of 7 HBeAg negative hepatitis B mothers. There was significant elevation of ALT in infants of HBeAg positive hepatitis B mothers (p<0.0001). The results suggest that the prevalence of NANB hepatitis was higher than hepatitis B in Korean pregnant women at the time of delivery. Duration of abnormal transaminase was similar in mothers with hepatitis B and NANB. The time of the earliest and highest elevation of ALT, the mean level of maximal elevation of ALT were similar in infants with hepatitis B and NANB. Duration of abnormal transaminase and maximal elevation of ALT seemed to be decreased by the immunoprophylaxis with HBIG and Hepavax for hepatitis B infants, gamma-globulin for NANB hepatitis infants, but there was a significant difference in hepatitis B infants whose mothers had HBeAg positivity.

B 형 간염 백신의 효과 - 산모의 HBeAg 양성 유무에 따라 -

김세종(Sei Jong Kim),윤종만(Chong Mann Yoon),최관수(Gwan Su Choi),김지운(Ji Woon Kim),정남기(nam Ki Joung),장영호(Yung Ho Chang),오은아(Eun A O),양인애(In Ae Yang),유영근(Young Geun Ryoo),이봉섭(Bong Seob Lee) 대한소화기학회 1988 대한소화기학회지 Vol.20 No.1

N/A The preventive efficacy for HBV infection and chronic HBV carrier rate by active and passive immunoprophylaxis was observed in 49 newborn infants whose mothers were healthy HBV carriers with normal ALT activity at delivery. All infants were divided into 3 groups; Group A received HBIG at birth and HB Vaccine (Hepavax- B) at month 0, 1 and 6. Group B received first or second vaccine only. Group C received no vaccine. ALT activity, HBsAg and anti-HBs were tested every 3 months for 18 rnonths after delivery, and the results were analyzed in 3 groups according to the mothers HBeAg positivity. 1) The anti-HBs response was57.1% (16/28) in Group A and 76.9% (10/13) in the control group whose mothers vere normal. The anti-HBs response was 64.3% (9.14) and 57.1% (8/14) according to the mothers HBeAg positivity and negativity. The anti-HBs response was 56.3% (9/16) in male and 66.7% (8/12) in female infants. The anti-HBs response svas higher in female infants and infants a hose mothers were normal or HBeAg positive carriers. 2) Chronic HBV carrier rate in infants of HBeAg positive mothers was 14.3% (2/l4) in Ciroup A, 72.7% (8/11 ) in Group 8, 100% (6/6) in Group c and was statistically significant (p=0.037) (c=0.816). There was no significant difference hetween group A, B, and C in infants of HBeAg negative mothers. 3) The positive rate of HBsAg showed significant difference between Groups A and B, A and C, A and (B+C), (A+B) and C in all 3 monthly follow-up tests in infants of HBeAg positive mothers. But there was no significant difference between (groups A, B, and C in infants of HBeAg negative mothers. The results suggest that the anti-HBs response was lower in infants of HBsAg carrier mothers. The preventive efficacy of vaccine for HBV infection and chronic HBV carrier rate was excellent in infants of HBeAg positive mothers but not significant in infants of HBeAg negative mothers by the active and passive immunoprophylaxis.